Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study
2024; Elsevier BV; Volume: 34; Linguagem: Inglês
10.1016/j.lana.2024.100750
ISSN2667-193X
AutoresMaría Eugenia Toledo-Romaní, Carmen Valenzuela‐Silva, Minerva Montero-Díaz, Luisa Iñiguez-Rojas, Meiby Rodríguez-González, Mery Martínez-Cabrera, Rinaldo Puga-Gómez, Angel German-Almeida, Sonsire Fernández-Castillo, Yanet Climent-Ruíz, Darielys Santana-Mederos, Lissette López-González, Ileana Morales-Suárez, Delaram Doroud, Yury Valdés-Balbín, Dagmar García-Rivera, Patrick Van der Stuyft, Vicente Vérez-Bencomo,
Tópico(s)COVID-19 Clinical Research Studies
ResumoIncreased pediatric COVID-19 occurrence due to the SARS-CoV-2 Omicron variant has raised concerns about the effectiveness of existing vaccines. The protection provided by the SOBERANA-02-Plus vaccination scheme against this variant has not yet been studied. We aimed to evaluate the scheme's effectiveness against symptomatic Omicron infection and severe disease in children.
Referência(s)